These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32004554)

  • 1. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
    Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
    Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry.
    Salisbury ML; Conoscenti CS; Culver DA; Yow E; Neely ML; Bender S; Hartmann N; Palmer SM; Leonard TB;
    Ann Am Thorac Soc; 2020 Nov; 17(11):1413-1423. PubMed ID: 32574517
    [No Abstract]   [Full Text] [Related]  

  • 3. Hospitalizations in patients with idiopathic pulmonary fibrosis.
    Kim HJ; Snyder LD; Adegunsoye A; Neely ML; Bender S; White ES; Conoscenti CS; Strek ME;
    Respir Res; 2021 Sep; 22(1):257. PubMed ID: 34592998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
    Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
    Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
    Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G
    Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry.
    O'Brien EC; Hellkamp AS; Neely ML; Swaminathan A; Bender S; Snyder LD; Culver DA; Conoscenti CS; Todd JL; Palmer SM; Leonard TB;
    Chest; 2020 May; 157(5):1188-1198. PubMed ID: 31954102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry.
    Swaminathan AC; Hellkamp AS; Neely ML; Bender S; Paoletti L; White ES; Palmer SM; Whelan TPM; Dilling DF;
    Ann Am Thorac Soc; 2022 Jun; 19(6):981-990. PubMed ID: 35073248
    [No Abstract]   [Full Text] [Related]  

  • 8. Lung function trajectories in patients with idiopathic pulmonary fibrosis.
    Neely ML; Hellkamp AS; Bender S; Todd JL; Liesching T; Luckhardt TR; Oldham JM; Raj R; White ES; Palmer SM
    Respir Res; 2023 Aug; 24(1):209. PubMed ID: 37612608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
    Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
    J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
    Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
    Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.
    de Andrade JA; Kulkarni T; Neely ML; Hellkamp AS; Case AH; Culver DA; Guntupalli K; Bender S; Conoscenti CS; Snyder LD;
    Respir Res; 2022 Jan; 23(1):3. PubMed ID: 34996465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).
    Rodríguez-Nieto MJ; Cano-Jiménez E; Romero Ortiz AD; Villar A; Morros M; Ramon A; Armengol S
    Pharmacoeconomics; 2023 Aug; 41(8):999-1010. PubMed ID: 37249823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study).
    Gómez AV; Rodríguez-Nieto MJ; Cano-Jiménez E; Ortiz AR; Morros M; Ramon A; Armengol S
    BMC Pulm Med; 2024 Jul; 24(1):370. PubMed ID: 39080648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.
    Yu YF; Macaulay DS; Reichmann WM; Wu EQ; Nathan SD
    Respir Med; 2015 Dec; 109(12):1582-8. PubMed ID: 26607877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital cost and length of stay in idiopathic pulmonary fibrosis.
    Mooney JJ; Raimundo K; Chang E; Broder MS
    J Med Econ; 2017 May; 20(5):518-524. PubMed ID: 28092235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.
    Case AH; Hellkamp AS; Neely ML; Bender S; Dilling DF; Gulati M; Hotchkin DL; Huie TJ; Lancaster L; Snyder LD; Conoscenti CS; Palmer SM
    Ann Am Thorac Soc; 2020 Jun; 17(6):699-705. PubMed ID: 32040340
    [No Abstract]   [Full Text] [Related]  

  • 18. Health Care Costs at the End of Life for Patients with Idiopathic Pulmonary Fibrosis. Evaluation of a Pilot Multidisciplinary Collaborative Interstitial Lung Disease Clinic.
    Kalluri M; Lu-Song J; Younus S; Nabipoor M; Richman-Eisenstat J; Ohinmaa A; Bakal JA
    Ann Am Thorac Soc; 2020 Jun; 17(6):706-713. PubMed ID: 32197048
    [No Abstract]   [Full Text] [Related]  

  • 19. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
    Todd JL; Neely ML; Overton R; Durham K; Gulati M; Huang H; Roman J; Newby LK; Flaherty KR; Vinisko R; Liu Y; Roy J; Schmid R; Strobel B; Hesslinger C; Leonard TB; Noth I; Belperio JA; Palmer SM;
    Respir Res; 2019 Oct; 20(1):227. PubMed ID: 31640794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.